FEATURED NEWS

• HDA Statement on Proposed DEA Regulations

  October 28, 2019

  In response to the Drug Enforcement Administration’s (DEA) proposed regulations related to the review and monitoring of annual production quotas, the Healthcare Distribution Alliance (HDA) released the following statement.

• Drew and Mauch Reelected to Lead HDA Board of Directors

  October 21, 2019

  The Healthcare Distribution Alliance (HDA) announced that Greg Drew, RPh, President of Value Drug Company, and Robert Mauch, PhD, PharmD, EVP and Group President of AmerisourceBergen Corporation, were recently elected to second terms as Chairman and Vice Chairman of the HDA Board of Directors.

• Key Excerpts from IG Review of the DEA's Efforts to Control the Diversion of Opioids

  October 1, 2019

  The following are excerpts from the recent report by the Office of the Inspector General, U.S. Department of Justice on the Drug Enforcement Administration’s (DEA) regulatory and enforcement efforts to control the diversion of opioids.

• HDA Statement on Inspector General's DEA Report

  October 1, 2019

  In response to the release of the U.S. Department of Justice Office of the Inspector General's Review of the Drug Enforcement Administration’s (DEA) Regulatory and Enforcement Efforts to Control the Diversion of Opioids, John Parker, Senior Vice President of Communications with the Healthcare Distribution Alliance (HDA) released the following statement.

• HDA Statement on the Ensuring Patient Access and Effective Drug Enforcement Act

  September 13, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement regarding media reporting on the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.